Another modulator of phosphorylation that can affect tau aggregation is davunetide, a small peptide whose efficiency has been tested in several in vitro and mouse models [276,277,278] and was tested in a phase III clinical trial for progressive supranuclear palsy, albeit with a negative outcome [279]. This evidence concerns the gene MAPT and progressive supranuclear palsy.